Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04374565 · ClinicalTrials.gov registry record · Phase 2
Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia
A Phase 2 study of Pneumonia and SARS-CoV-2, sponsored by University of Virginia.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 2
- Study locations
NCT04374565 is a Phase 2 study of Pneumonia and SARS-CoV-2 that has completed, run by University of Virginia. The registered enrollment target is 29 participants, below the 4,519-participant average among 47 other Pneumonia trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT04374565, a Phase 2 study of Pneumonia and SARS-CoV-2, has completed, sponsored by University of Virginia.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a single arm phase II trial to assess efficacy and confirm safety of infusions of anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory symptoms,with or without confirmed interstitial COVID-19 pneumonia by chest Xray or CT. A total of 29 eligible subjects will be enrolled to receive anti-SARS-CoV-2 plasma.Outcomes will be compared to hospitalized controls with confirmed COVID-19 disease through retrospective chart review.
Conditions Studied
Interventions
- DRUG High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma
Study Locations (2)
Virginia
- University of Virginia Medical Center - Charlottesville
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2020-05-05 |
| Est. Completion | 2021-03-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04374565
The ClinicalTrials.gov registry entry for NCT04374565 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,519-participant average among 47 other Pneumonia trials with a reported enrollment target (99% lower). The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Pneumonia appearing as the primary indexed condition, and to 1 intervention - of which High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma is the first listed.
NCT04374565 reports 2 study locations spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT04374565 about?
NCT04374565 is a clinical study titled "Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia". This is a single arm phase II trial to assess efficacy and confirm safety of infusions of anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory symptoms,with or without confirmed interstitial COVID-19 pneumonia by chest Xray or CT. A total of 29 eligible subjects will b...
What is the current status of trial NCT04374565?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2020-05-05. Estimated completion is 2021-03-05.
What conditions does trial NCT04374565 study?
This clinical trial studies the following conditions: Pneumonia, SARS-CoV-2, Corona Virus Infection, SARS Pneumonia.
What interventions are being tested in trial NCT04374565?
The interventions under investigation include: High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma (DRUG).
Who is sponsoring clinical trial NCT04374565?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04374565 being conducted?
This trial has 2 study locations across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pneumonia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Individualizing Corticosteroid Use in Pneumonia
RECRUITING · Phase 2
-
Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.
RECRUITING · Phase 2
-
Low-Dose Radiotherapy For Patients With SARS-COV-2 (COVID-19) Pneumonia
ACTIVE NOT RECRUITING · Phase 2
-
Steroid Dosing by bioMARker Guided Titration in Critically Ill Patients With Pneumonia
COMPLETED · Phase 2
-
A Study of Auxora in Patients With Severe COVID-19 Pneumonia
COMPLETED · Phase 2
-
Safety, Tolerability and Pharmacokinetics of Aerosolized Amikacin in Intubated and Mechanically-ventilated Patients With Nosocomial Pneumonia
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.